The Consequence Library · How records are made and graded
The FDA issued a warning letter to Purolea Cosmetics Lab that, for the first time, carved out an enforcement deficiency section specifically on inappropriate use of artificial intelligence, after the firm used AI agents to create drug product specifications, procedures and master production records without documented review by a qualified person before use.
Evidence caveat. A warning letter states the agency's findings and is not an adjudication. The firm is small and the products at issue are limited; the record is included for the regulatory precedent it sets, not for the scale of the consequence.
What happened
The FDA inspected the firm's drug manufacturing facility in Livonia, Michigan from 28 to 30 October 2025 and issued warning letter MARCS-CMS 722591 on 2 April 2026. The letter cites significant violations of current good manufacturing practice regulations for finished pharmaceuticals. During the inspection the firm stated it had used AI agents to create drug product specifications, procedures and master production or control records to help comply with FDA requirements. The agency's position, recorded in the letter, is that firms using AI to assist document creation must review the resulting documents for accuracy and compliance before use, and it cited the failure to do so under the quality unit regulation at 21 CFR 211.22(c).
Where control failed
The generated document entered the quality system as though it had been authored and checked. There was no gate requiring a qualified person to review AI-generated content before it became a controlled record, and no record of such review to produce when an inspector asked.
The authority question
Formal authority over specifications and master records belongs to the quality unit. Here the content originated with a system that holds no such authority and cannot be held to it, and the quality unit's approval step did not interpose an actual review. The regulator treated the absence of documented human review as the violation.
What could be proven afterward
The record here is unusually clean because a regulator created it. The warning letter is a primary public document that states what the firm said during the inspection and what the agency concluded. That is the opposite of the pattern in most records in this library, where the evidence had to be compelled or was never produced.
Control state, before and after
Before the consequence
AI-generated specifications and master records entering the quality system with no documented qualified-person review before use.
After the consequence
FDA warning letter citing the quality unit regulation, published publicly on 2 April 2026.
Sources
- Primary: FDA, Warning Letter to Purolea Cosmetics Lab, MARCS-CMS 722591, 2 Apr 2026 · https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026
- Secondary: RAPS, "FDA warns firm for inappropriate use of AI in drug manufacturing" · https://www.raps.org/resource/fda-warns-firm-for-inappropriate-use-of-ai-in-drug-manufacturing.html
Record history
Published 16 August 2026. Load-bearing facts re-verified against the cited sources on 16 August 2026. Corrections and material changes are appended here with their dates. To report an error in this record, write to hello@regulayer.com with the record slug and the source you believe is authoritative.
This record describes what sources establish about a consequence and the control state around it. It separates confirmed fact from source-stated cause and from architectural analysis, and it makes no claim that any control or product would have prevented the outcome. Gap codes identify a failure class, not a remedy.